Switch theme
Sign up to access all valuation multiples
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of major metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
2014
38
LTM Revenue $1.9M
LTM EBITDA -$10.8M
$14.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Valbiotis has a last 12-month revenue (LTM) of $1.9M and a last 12-month EBITDA of -$10.8M.
In the most recent fiscal year, Valbiotis achieved revenue of $0.2M and an EBITDA of -$10.3M.
Valbiotis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Valbiotis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | $1.9M | XXX | -$2.7M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | -1396% | XXX | XXX | XXX |
| EBITDA | -$10.8M | XXX | -$10.3M | XXX | XXX | XXX |
| EBITDA Margin | -564% | XXX | -5241% | XXX | XXX | XXX |
| EBIT | -$11.2M | XXX | -$11.7M | XXX | XXX | XXX |
| EBIT Margin | -585% | XXX | -5957% | XXX | XXX | XXX |
| Net Profit | -$11.1M | XXX | -$11.3M | XXX | XXX | XXX |
| Net Margin | -580% | XXX | -5729% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Valbiotis's stock price is EUR 1 (or $1).
Valbiotis has current market cap of EUR 18.7M (or $21.0M), and EV of EUR 12.9M (or $14.5M).
See Valbiotis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.5M | $21.0M | XXX | XXX | XXX | XXX | $-0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Valbiotis has market cap of $21.0M and EV of $14.5M.
Valbiotis's trades at 73.6x EV/Revenue multiple, and -1.4x EV/EBITDA.
Equity research analysts estimate Valbiotis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Valbiotis has a P/E ratio of -1.9x.
See valuation multiples for Valbiotis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.0M | XXX | $21.0M | XXX | XXX | XXX |
| EV (current) | $14.5M | XXX | $14.5M | XXX | XXX | XXX |
| EV/Revenue | 7.5x | XXX | 73.6x | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | -1.4x | XXX | XXX | XXX |
| EV/EBIT | -1.3x | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | 7.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -1.9x | XXX | XXX | XXX |
| EV/FCF | -1.3x | XXX | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialValbiotis's last 12 month revenue growth is 160%
Valbiotis's revenue per employee in the last FY averaged $5K, while opex per employee averaged $0.2M for the same period.
Valbiotis's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Valbiotis's rule of X is -164% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Valbiotis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 160% | XXX | 586% | XXX | XXX | XXX |
| EBITDA Margin | -564% | XXX | -5241% | XXX | XXX | XXX |
| EBITDA Growth | -31% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | -5081% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -164% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $5K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2650% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4561% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Valbiotis acquired XXX companies to date.
Last acquisition by Valbiotis was XXXXXXXX, XXXXX XXXXX XXXXXX . Valbiotis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Valbiotis founded? | Valbiotis was founded in 2014. |
| Where is Valbiotis headquartered? | Valbiotis is headquartered in France. |
| How many employees does Valbiotis have? | As of today, Valbiotis has 38 employees. |
| Is Valbiotis publicy listed? | Yes, Valbiotis is a public company listed on PAR. |
| What is the stock symbol of Valbiotis? | Valbiotis trades under ALVAL ticker. |
| When did Valbiotis go public? | Valbiotis went public in 2017. |
| Who are competitors of Valbiotis? | Similar companies to Valbiotis include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Valbiotis? | Valbiotis's current market cap is $21.0M |
| What is the current revenue of Valbiotis? | Valbiotis's last 12 months revenue is $1.9M. |
| What is the current revenue growth of Valbiotis? | Valbiotis revenue growth (NTM/LTM) is 160%. |
| What is the current EV/Revenue multiple of Valbiotis? | Current revenue multiple of Valbiotis is 7.5x. |
| Is Valbiotis profitable? | Yes, Valbiotis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Valbiotis? | Valbiotis's last 12 months EBITDA is -$10.8M. |
| What is Valbiotis's EBITDA margin? | Valbiotis's last 12 months EBITDA margin is -564%. |
| What is the current EV/EBITDA multiple of Valbiotis? | Current EBITDA multiple of Valbiotis is -1.3x. |
| What is the current FCF of Valbiotis? | Valbiotis's last 12 months FCF is -$11.1M. |
| What is Valbiotis's FCF margin? | Valbiotis's last 12 months FCF margin is -579%. |
| What is the current EV/FCF multiple of Valbiotis? | Current FCF multiple of Valbiotis is -1.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
